Companies: 10,795·Total market cap: $144.5T
X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc.

XFORNASDAQHealthcare● Active
$3.88
+$0.17(+4.58%)
Market Cap$365960420
P/E Ratio
52W High$4.83
52W Low$1.35
Overview

X4 Pharmaceuticals, Inc. (XFOR) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001501697 · XFOR · NASDAQ · as of Jun 9, 2026

Filing snapshot

794
Total Filings
SCHEDULE 13G/A
Latest Form
2026-05-15
Most Recent
2017
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001501697 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-17
Fiscal Year End
Mar 17, 2026
Accession No.
0001501697-26-000018
Primary Document
xfor-20251231.htm
Source: data.sec.gov · CIK 0001501697 · Accession 0001501697-26-000018

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-06
8-KCurrent Report
8-K/A
2026-05-13Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
EFFECTEFFECT
EFFECT
2026-05-14
View
8-K/ACurrent Report (Amended)
8-K/A
2026-05-13
View
8-KCurrent Report
8-K
2026-05-12
View
S-3Shelf Registration
S-3
2026-05-06
View
10-QQuarterly Report
10-Q
2026-05-06
View
ARSARS
ARS
2026-03-20
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-03-20
View
DEF 14AProxy Statement
DEF 14A
2026-03-20
View
S-8Employee Stock Plan Registration
S-8
2026-03-18
View
10-KAnnual Report
10-K
2026-03-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-06
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
Showing 1–15 of 491 filingsForm 4 / 144 hidden· 794 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001501697  |  Exchange: NASDAQ · Healthcare

X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) has submitted 794 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2017. As a Healthcare sector company with CIK 0001501697, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is X4 Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent X4 Pharmaceuticals, Inc. 10-K was filed on 2026-03-17 for fiscal year ending 2026. Historical XFOR 10-K annual reports are available from 2010 through 2026.

Investors researching X4 Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

XFOR SEC Filings · 8 questions

X4 Pharmaceuticals, Inc. (XFOR) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 794 filings and access original documents at no cost. X4 Pharmaceuticals, Inc.'s CIK is 0001501697.

XFOR SEC filingsX4 Pharmaceuticals, Inc. SEC documentsfind XFOR 10-K